CTAD 2026: 5 Alzheimer's Abstracts That Could Move Stocks

Every biotech investor knows AAIC moves Alzheimer’s stocks. Fewer screen CTAD systematically, and that is the edge. CTAD, the Clinical Trials on Alzheimer’s Disease conference, runs November 16 through 19 in Boston this year. The trade fires weeks before the podium. Regular abstracts release roughly two to three weeks before the meeting, in late October, and the program lands in a Journal of Prevention of Alzheimer’s Disease supplement after the event. If you wait for the presenter to step up, the stock has already gapped. This is the forward twin of the ASH 2026 preview, transposed from blood cancers to the slowest, most failure-prone corner of biotech.

The pattern repeats every November. A tau name drops a dataset that surprises the Street, the stock gaps 15-30% overnight, and the anti-amyloid updates that dominate CTAD headlines barely twitch the mega-caps. The edge is screening the small and mid-cap names where the data actually changes the thesis. Here are five to watch, ranked by stock-moving potential.

1. Biogen Diranersen: The Tau Trade Has a Second Checkpoint

Biogen closed at $227.60, a $33.6 billion market cap. Two Alzheimer’s datasets land at CTAD, and only one re-rates the stock. The first is Leqembi (lecanemab): Eisai and Biogen will roll out more subcutaneous and real-world follow-up on the back of the July LEADER readout that showed over 75% of early Alzheimer’s patients remained stable and nearly 7% improved over an average of 17 months. That is incremental, not binary. The subcutaneous initiation approval already landed July 13, and the three-year data is already public.

The binary is diranersen (BIIB080), the antisense oligonucleotide that reduces tau production. The Phase 2 CELIA data from AAIC missed its primary endpoint on a dose-response technicality, but the 60 mg arm slowed decline 26% on CDR-SB, 42% on ADAS-Cog13, and 50% on MMSE while cutting CSF tau 50-65%. The abstract to screen for at CTAD is any diranersen follow-up: the Phase 3 design, the dosing resolution for the inverse dose-response, and whether Biogen commits to a registrational timeline. The full CELIA breakdown and the Alzheimer’s pipeline are covered. If the Phase 3 design lands with a clear 60 mg strategy, Biogen re-rates toward the $40-50 billion range. If the dosing question stays unresolved, the tau option stays at zero. The risk is the graveyard: 99% of Alzheimer’s Phase 3s fail, and the inverse dose-response is an unanswered red flag. The CELIA trial is the external reference.

2. Roche Trontinemab: The Anti-Amyloid Challenger That Re-rates the Field

Roche trades near $54 on the ADR, a mega-cap that will not move on trontinemab. Rank it anyway, because trontinemab is the competitive read-through that matters in the anti-amyloid class. The BrainShuttle bispecific cleared amyloid below the 24-centiloid threshold in 91% of patients at 28 weeks, with 72% achieving deep clearance below 11 centiloids, and ARIA-E below 5% versus 13% for lecanemab and 24% for donanemab. Phase 3 TRONTIER 1 and 2 are enrolling in early symptomatic disease, and PrevenTRON is the prevention trial in cognitively unimpaired people at high risk.

The abstract to screen for is the long-term safety and amyloid-removal data from the BRAINSHUTTLE open-label extension, plus any TRONTIER enrollment signal. The re-rate is not on Roche. It is on Biogen and Lilly: if trontinemab’s cleaner safety profile holds at scale, the Leqembi/Kisunla bull case compresses, and the anti-amyloid franchise multiple for every incumbent gets marked down. That ARIA-E gap is the whole story, because ApoE4 homozygotes, the patients most likely to progress fastest, are exactly the patients an antibody with a 5% edema rate can treat with far less MRI-monitoring friction than one with a 13% or 24% rate. Roche’s AAIC presentation established the benchmark; CTAD is the confirmation layer.

3. Prothena Moponetug: The Other Tau Bet

Prothena closed at $8.29, a $425 million market cap, and it is the cleanest small-cap way to own the anti-tau thesis that diranersen just validated. Moponetug (BMS-986446), the anti-MTBR tau antibody Prothena discovered and Bristol Myers Squibb licensed, is in the Phase 2 TargetTau-1 trial with Fast Track designation. Unlike diranersen’s antisense approach, moponetug is an antibody targeting the microtubule-binding region of tau, the same pathogenic species but a different mechanism.

The abstract to screen for is any TargetTau-1 biomarker update: MTBR tau reduction, pTau217 movement, or dose escalation data. The re-rate thesis is simple. The tau hypothesis now has its first randomized Phase 2 cognitive signal, and every tau name re-rates off that halo. Prothena at $425 million prices moponetug at near-zero; a positive tau biomarker signal could double it. The risk is timing: TargetTau-1 primary completion is not until the first half of 2027, so CTAD 2026 is likely design and biomarker, not efficacy. That is a re-rate on signal, not proof.

4. AC Immune: The Micro-Cap Tau Vaccine

AC Immune closed at $2.52, a $250 million market cap. It is the highest-beta name on the list and the smallest. The lead program is ACI-35.030, an anti-pTau vaccine in Phase 1b/2a, plus antibody programs targeting tau pathology. The abstract to screen for is anti-pTau immunogenicity data: does the vaccine generate a durable antibody response against phosphorylated tau without the safety problems that killed earlier active immunotherapy attempts.

The re-rate thesis is that the tau theme, once it catches, flows down to the micro-caps first because the percentage move is largest. The risk is everything else: a vaccine approach has no proof of concept, the company needs cash, and a $250 million name can halve on a single financing. This is a lottery ticket, not a thesis, and it deserves no more than a half-percent position.

5. Quanterix: The Picks-and-Shovels Read

Quanterix closed at $3.27, a $155 million market cap, and it is the diagnostics tailwind that every Alzheimer’s drug depends on. The LucentAD pTau217 blood test secured Anthem commercial coverage in July, and Roche’s competing Elecsys pTau217 earned CE Mark in May. The abstract to screen for at CTAD is any pTau217 clinical utility data: head-to-head accuracy against PET, real-world primary-care performance, or coverage-expansion signals. The re-rate thesis is the screening inflection: roughly 75% of dementia patients are undiagnosed, and a routine blood test expands the diagnosed pool 5-10x, which builds the market for every anti-amyloid and anti-tau drug. The Alzheimer’s pipeline covers the diagnostics tailwind. The risk is reimbursement and the fact that Roche, a far better-capitalized competitor, owns the automated-assay channel.

The Mega-Cap Filter

This list excludes the two names that will dominate CTAD headlines and move zero basis points. Eli Lilly at $1.05 trillion does not move on donanemab, remternetug, or the oral GLP-1 orforglipron. Novo Nordisk at roughly $170 billion is the cautionary tale: oral semaglutide failed both EVOKE and EVOKE+ with a 0.06-point CDR-SB miss, and the GLP-1-for-Alzheimer’s hypothesis is dead, as covered in the post-mortem. The filter is simple: if the market cap exceeds $100 billion and the indication is Alzheimer’s, the data does not move the stock.

The Catalyst-Consumed Caveat

The same lesson from the ESMO preview applies here. Some of what looks like a CTAD catalyst already resolved. Diranersen’s Phase 2 CELIA data already dropped at AAIC in July; CTAD is follow-up, not a first look. Leqembi’s subcutaneous initiation approval already landed July 13. The semaglutide GLP-1 story is already dead. Verify what is priced before you trade any of these names on abstract day.

The playbook is covered in the biotech conference trading guide: abstract release is the trade date, position size 1-2% per binary event, and IV crush after the abstract drop is real whether the data is good or bad. Do not hold a conference catalyst past the first trading day after abstract release.

The verdict: screen Biogen first, then Prothena. Those are the two names where CTAD 2026 data actually re-rates the stock. Biogen is the trade because diranersen is the only tau asset with a randomized cognitive signal, and a clean Phase 3 design commit is a catalyst the market has not priced. Prothena is the higher-beta ride on the same thesis, smaller and faster-moving, but its data at CTAD is likely biomarker rather than efficacy. Roche trontinemab sets the competitive map but moves zero basis points on a mega-cap ADR, and it re-rates Biogen’s Leqembi franchise either way.